Open AccessCD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
Author(s) -
Liyan Qiao,
Han-Bing Li,
Yue Zhang,
Di Shen,
Peng Liu,
YiQun Che
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s310816
Subject(s) - cd24 , chop , medicine , lymphoma , diffuse large b cell lymphoma , oncology , cancer research , cancer , breast cancer
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma and of which the prognosis of activated B-cell-like (ABC) subtype is poor. Although R-CHOP significantly improves the survival of patients with DLBCL, 20% to 40% of patients were resistant to R-CHOP therapy. Thus, screening for candidate therapeutic targets for R-CHOP resistant patients is urgent. The previous researches have shown that CD24 is related to the development, invasion, and metastasis of cancer. Our project aims to clarify the relationship between CD24 and ABC-DLBCL.